onkommon.com
Programme R10
Health Economics & Access Modelling
At what price does molecular testing stop costing money and start saving it?
The problem
Precision oncology is argued for on clinical grounds and rejected on financial ones. Almost no Indian cost-effectiveness evidence exists to settle the argument either way.
Treatment abandonment, patients stopping because of cost, is the largest single failure in Indian cancer care, and it is barely quantified.
The questions
- What does precision oncology cost per quality-adjusted year in an Indian setting?
- At what price does molecular testing become cost-saving rather than cost-adding?
- What actually drives treatment abandonment, and which interventions reduce it?
What we are contributing
We run a cost desk as a clinical service, which means we hold real total-course cost data alongside real outcomes, the two things a health economist normally has to estimate separately.
Studying abandonment properly requires knowing who stopped and why. Because navigation follows every patient, we know. Most institutions record only that the patient did not return.
How the work is done
- Cost-effectiveness and budget-impact modelling
- Decision-analytic models
- Abandonment and adherence analysis
- Biosimilar switching economics
- Screening programme economics
What it runs on
- Our own cost and outcome data
- Scheme and reimbursement data
- Published cost inputs
What it produces
- Cost-effectiveness evidence for Indian precision oncology
- Abandonment-driver analysis
- Health-technology assessment submissions
- Publications
Why it is not just science
How this changes care here
- Underwrites the cost desk and the biosimilar programme
- The strongest public-tender positioning the institution has
- Evidence for scheme and payer conversations
Funding fit
Public tenders and health-technology assessment programmes; international health-policy funders.
What we are looking for
- Health economists
- Policy and payer collaborators
- Funding for abandonment cohort studies
Deliberately empty
Publications, funding and results
Nothing appears in this section until it exists in writing. No paper in preparation, no grant under review, no result not yet published. That rule applies with particular force to a research page.